Navigation Links
Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
Date:10/30/2008

JERUSALEM, October 30 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery systems, announced today that its Chief Executive Officer, Mr. Nadav Kidron, will be giving a company presentation at the 10th Annual Rodman & Renshaw Healthcare Conference at New York City's Palace Hotel on November 11. Mr. Kidron is scheduled to present from 4:05 - 4:30 in the Kennedy II Ballroom, located on the 4th floor of the hotel.

"The Rodman & Renshaw Conference will give Oramed an important platform to present the accomplishments we have achieved in our development of an oral insulin capsule and our unique position as a technology pioneer in the field of oral delivery solutions," said Kidron.

For more information about Rodman & Renshaw and the upcoming conference, please visit http://www.rodmanandrenshaw.com/conferences.

For more information about Oramed Pharmaceuticals, please visit http://www.oramed.com.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which
'/>"/>

SOURCE Oramed Pharmaceticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
2. Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)
3. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
4. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
5. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
6. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
7. Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
8. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
9. Memory Pharmaceuticals Provides Update on NASDAQ Listing Status
10. BioWa Announces License of Biowas Potelligent(R) Technology to KaloBios Pharmaceuticals
11. Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014  Ascendis Pharma A/S, ... technology to address significant unmet medical needs, today ... 2 pediatric study to evaluate once-weekly TransCon Growth ... GHD.  The full interim results will be presented ... and IGF Society, being held October 15-18, 2014, ...
(Date:9/16/2014)... September 16, 2014 BCC Research ... FOR STEM CELLS , the global market for stem ... by 2018, with a five-year compound annual growth rate ... in the Americas with growth projections of $2.2 billion ...      (Logo: http://photos.prnewswire.com/prnh/20140805/700528) , Unlike other potential ...
(Date:9/16/2014)... 2014 RENU 28, the world's first and ... available for purchase in Australia and New Zealand in mid-August ... September 16th. The tour will make stops in Brisbane on ... the 18th, Sydney on the 20th, and Melbourne on the ... New Zealand and to educate people about the new product ...
(Date:9/15/2014)... , Sept. 15, 2014   Global Science ... of scientific products and services for satellite and ... Solution for Integrated Services (OASIS) from the General ... was selected to provide the government best-value solutions ... Business (SB) category in Pool 4. The OASIS ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 2Global Market for Stem Cells to Reach $10.6 Billion in 2018; The Americas Growing at 13.9% CAGR 3Global Wellness Company Hosts ASEA Australia Tour September 16-22 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 3
... Biomerica,Inc. (OTC Bulletin Board: BMRA) has introduced a ... announced that it received CE mark approval to,market and ... in,the European Union. The product will be marketed under ... people in the U.S. are allergic to cat dander,the ...
... 18 Forest Laboratories, Inc.,(NYSE: FRX ) and ... the novel beta,blocker Bystolic(TM) (nebivolol) was approved by the ... hypertension. Bystolic is a once,daily medication that can be ... affects approximately 72 million,adults in the U.S. and 65 ...
... Using the latest methods for nanofabrication, a team led ... electronic property in one of the earliest-known and most-studied ... magnetite. , By changing the voltage in their experiment, ... than minus 250 degrees Fahrenheit to revert from an ...
Cached Biology Technology:Biomerica Introduces a New 15 Minute Home Test for Allergies to Cats and Receives CE Mark Approval for Home Use 2Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension 2Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension 3Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension 4Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension 5New property found in ancient mineral lodestone 2
(Date:9/16/2014)... is associated with increased rates and intensity of tobacco ... the relationship between schizophrenia and smoking stems, in part, ... self-medicate symptoms and cognitive impairment associated with the disease. ... of Biological Psychiatry , sheds light on this ... receptors in the brain was lower in schizophrenia patients ...
(Date:9/16/2014)... responsible for practically all vital functions in an ... signals, transport particular substances and control immune system ... do not function independently of each other, but ... the protein networks, you find many similarities with ... TUM,s Chair of Plant Systems Biology. "Some proteins ...
(Date:9/15/2014)... Human skin and gut microbes influence processes from digestion ... are the most biodiverse terrestrial ecosystems on the planet, ... trees in the tropics. Smithsonian scientists and colleagues working ... samples from a single tree were home to more ... from 57 tree species contained more than 7,000 different ...
Breaking Biology News(10 mins):Smoking and schizophrenia linked by alterations in brain nicotine signals 2Good networkers make prime targets 2Smithsonian scientists discover tropical tree microbiome in Panama 2
... enemy of the good, but in the nanoscale world, perfection can ... world, engineers and scientists go to great lengths to make the ... a light switch or turn the key on the car, we ... every time, with only rare exceptions. They have done so by ...
... (President Ryoji Noyori) and the Max Planck Society (MPG; ... 2011, to strengthen their collaboration by ,establishing a joint ... seeks to ,achieve a systematic understanding of biological systems ... research center will bring together the RIKEN Advanced Science ...
... that parents can fill out in pediatrician waiting rooms may ... disorder (ASD) , according to a study funded by the ... of Pediatrics , the study,s design also provides a model ... change to their practice. "Beyond this exciting proof of ...
Cached Biology News:Nanotechnologists must take lessons from nature 2Nanotechnologists must take lessons from nature 35-minute screen identifies subtle signs of autism in 1-year olds 2
... clone d1-174 GenBank Accession Number : ... N-terminal tagged fusion protein corresponding to full ... Tris-glycine, pH 7.4, 0.15M NaCl, 0.05% sodium ... 30% Quality Assurance: routinely evaluated by immunoblot ...
...
X-Gal, 1 g. 5-Bromo-4-chloro-3-indolyl-b-d-galactoside.Histochemical substrate for b-galactosidase, used in blue/white screening.Store at -20 C. Protect from moisture. Category: Nucleotides & Enzymes...
Conjugation services for Antibodies, Proteins, Oligos, Peptides, Beads, bioconjugation, antibody-oligonucleotide, LNA peptide, LNA protein, LNA antibody, HRP, Alkaline phosphatase, phycoerythrin, FIT...
Biology Products: